Clinical practice guideline for chronic myelogenous leukemia and its practice in China
JIANG Hao
HUANG Xiao-jun
Abstract：Imatinib mesylate,as the first generation Bcr-Abl tyrosine kinase inhibitor,has brought revolutionary treatment for Philadelphia chromosome(Ph)-positive chronic myelogenous leukemia(CML);it has been recommended as the first-line treatment for CML by NCCN Practice Guidelines in Oncology in 2008 and European Leukemia Net(ELN)criteria.However,imatinib has three limitations:first,it is expensive and can not be stopped if efficancy to be maintained;Second,some 20%～30%of patients develope resistance to imminib;and third,the CML patients can not be cured with imatinib.Taking into consideration of the situation in China,we recommend individual therapy using TKI,HSCT,interferon and cytotoxic drugs for CML patients in China.
Keywords：chronic myelogenous leukemiahematopoetic stem cell transplantationimatinib
Publication Date：2010-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 32-34 )